{"version":"1.0","type":"link","title":"A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer.","author_name":"Miller KD 외","author_url":"https://prs-insight.online/author/Miller%20KD","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/76584","thumbnail_width":1200,"thumbnail_height":630}